RT Journal Article
T1 Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response.
A1 Perez-Gomez, Alberto
A1 Gasca-Capote, Carmen
A1 Vitalle, Joana
A1 Ostos, Francisco J
A1 Serna-Gallego, Ana
A1 Trujillo-Rodriguez, Maria
A1 Muñoz-Muela, Esperanza
A1 Giraldez-Perez, Teresa
A1 Praena-Segovia, Julia
A1 Navarro-Amuedo, Maria D
A1 Paniagua-Garcia, Maria
A1 Garcia-Gutierrez, Manuel
A1 Aguilar-Guisado, Manuela
A1 Rivas-Jeremias, Inmaculada
A1 Jimenez-Leon, Maria Reyes
A1 Bachiller, Sara
A1 Fernandez-Villar, Alberto
A1 Perez-Gonzalez, Alexandre
A1 Gutierrez-Valencia, Alicia
A1 Rafii-El-Idrissi Benhnia, Mohammed
A1 Weiskopf, Daniela
A1 Sette, Alessandro
A1 Lopez-Cortes, Luis F
A1 Poveda, Eva
A1 Ruiz-Mateos, Ezequiel
K1 COVID-19
K1 IL-2
K1 SARS-CoV-2
K1 Spike
K1 T-cell response
K1 endemic coronaviruses
K1 nucleocapsid
K1 polyfunctionality
AB SARS-CoV-2 specific T-cell response has been associated with disease severity, immune memory and heterologous response to endemic coronaviruses. However, an integrative approach combining a comprehensive analysis of the quality of SARS-CoV-2 specific T-cell response with antibody levels in these three scenarios is needed. In the present study, we found that, in acute infection, while mild disease was associated with high T-cell polyfunctionality biased to IL-2 production and inversely correlated with anti-S IgG levels, combinations only including IFN-γ with the absence of perforin production predominated in severe disease. Seven months after infection, both non-hospitalised and previously hospitalised patients presented robust anti-S IgG levels and SARS-CoV-2 specific T-cell response. In addition, only previously hospitalised patients showed a T-cell exhaustion profile. Finally, combinations including IL-2 in response to S protein of endemic coronaviruses were the ones associated with SARS-CoV-2 S-specific T-cell response in pre-COVID-19 healthy donors' samples. These results could have implications for protective immunity against SARS-CoV-2 and recurrent COVID-19 and may help for the design of new prototypes and boosting vaccine strategies.
PB John Wiley & Sons Ltd.
YR 2022
FD 2022-04-12
LK http://hdl.handle.net/10668/21873
UL http://hdl.handle.net/10668/21873
LA en
NO Pérez-Gómez A, Gasca-Capote C, Vitallé J, Ostos FJ, Serna-Gallego A, Trujillo-Rodríguez M, et al. Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response. Clin Transl Med. 2022 Apr;12(4):e802.
DS RISalud
RD May 10, 2025